



(Rel.88-11/01 Pub.605)

FORM 9-37

9-221

RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

Practitioner's Docket No. NEB-181

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Vaisvila

Application No.: 09 / 689,343 Group No.: 1636

Filed: October 12, 2000

Examiner: D. Guzo

For: Method For Cloning And Producing The MseI Restriction Endonuclease

#16D
Zeta
10-16-02

Box Sequence

Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1. ☒ This replies to the Office Letter dated September 24, 2002

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the application number from the return post card or the attorney's docket number added.

- ☒ A copy of the Office Letter is enclosed.

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

37 C.F.R. § 1.8(a)

37 C.F.R. § 1.10*

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"

Mailing Label No. _____ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office

Signature

Melissa A. Jackson

(type or print name of person certifying)

*WARNING: Each paper or fee filed by Express Mail must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. § 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

10/11/2002 HBERHE

00000007 09689343

(Submission—Nucleotide and/or Amino Acid Sequence [9-37]—page 1 of 6)

01 FC:216

200.00 OP

BEST AVAILABLE COPY



IDENTIFICATION OF PERSON MAKING STATEMENT

2.

I, Harriet M. Strimpel

(type or print name of declarant signing below)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

(check each item as applicable)

- A. ☒ "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate Identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823.
- B. ☐ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned Identifier, as required in 37 C.F.R. § 1.821(d).
- C. ☒ A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.
- D. ☐ Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Application No.: 0 /

Filed:

For:

Group No.:

Examiner:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form
(other application)

"Sequence Identifier"
(this application)

(Submission—Nucleotide and/or Amino Acid Sequence [9-37]—page 2 of 6)

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. § 1.821(e).

- E. ☒ A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).
- ☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified as required in 37 C.F.R. § 1.821(b).
- F. ☒ Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.
- ☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g).

STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. ☒ Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. ☒ All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5. Applicant is

- ☒ a small entity. A statement:
- ☐ is attached.
- ☒ was already filed.
- ☐ other than a small entity.

(Submission—Nucleotide and/or Amino Acid Sequence [9-37]—page 3 of 6)

BEST AVAILABLE COPY

EXTENSION OF TERM

6.

NOTE: 37 C.F.R. § 1.704(b) ". . . an applicant shall be deemed to have failed to engage in reasonable efforts to conclude processing or examination of an application for the cumulative total of any periods of time in excess of three months that are taken to reply to any notice or action by the Office making any rejection, objection, argument, or other request, measuring such three-month period from the date the notice or action was mailed or given to the applicant, in which case the period of adjustment set forth in § 1.703 shall be reduced by the number of days, if any, beginning on the day after the date that is three months after the date of mailing or transmission of the Office communication notifying the applicant of the rejection, objection, argument, or other request and ending on the date the reply was filed. The period, or shortened statutory period, for reply that is set in the Office action or notice has no effect on the three-month period set forth in this paragraph."

NOTE: "Extension of Time in Patent Cases (Supplement Amendments)—If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. § 1.645 for extensions of time in interference proceedings and 37 C.F.R. § 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136 apply.

(complete (a) or (b) as applicable)

(a) ☒ Applicant petitions for an extension of time under 37 C.F.R. § 1.136 (fees: 37 C.F.R. § 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity
<input type="checkbox"/> one month	\$ 110.00	\$ 55.00
<input type="checkbox"/> two months	\$ 400.00	\$ 200.00
<input checked="" type="checkbox"/> three months	\$ 920.00	\$ 460.00
<input type="checkbox"/> four months	\$ 1,440.00	\$ 720.00

Fee: \$ 200.00

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

☐ An extension for _____ months has already been secured. The fee paid therefor of \$_____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$ 200.00

OR

(b) ☐ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

(Submission—Nucleotide and/or Amino Acid Sequence [9-37]—page 4 of 6)

FEE PAYMENT

8. ☒ Attached is a ☒ check ☐ money order in the amount of \$ 200.00
☐ Authorization is hereby made to charge the amount of \$ _____
☐ to Deposit Account No. _____
☐ to Credit card as shown on the attached credit card information authorization form PTO-2038.

WARNING: Credit card information should **not** be included on this form as it may become public.

- ☒ Charge any additional fees required by this paper or credit any overpayment in the manner authorized above.

A duplicate of this paper is attached.

FEE DEFICIENCY

9.

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. ☒ If any additional extension and/or fee is required, charge
☒ Deposit Account No. 14-0740
☐ Credit card as shown on the attached credit card information authorization form PTO-2038.

WARNING: Credit card information should **not** be included on this form as it may become public.

SIGNATURE(S)

Harriet M. Strimpel

(type or print name of person signing statement)

Sept 30, 2002

Date

Harriet Strimpel

Signature

P.O. Address of Signatory

(if applicable)


Telephone No. (978) 927-5054 X:373

Reg. No. 37008

Customer No.: 28986

- ☐ Inventor(s)
☐ Assignee of complete interest
☐ Person authorized to sign on behalf of assignee
☒ Practitioner of record
☐ Filed under Rule 34(a)
☒ Registration No. 37008
☐ Other _____

(specify identity of declarant)



(complete the following, if applicable)

New England Biolabs, Inc.

(type name of assignee)

32 Tozer Road

Address of assignee

Beverly, MA 01915

Secretary

Title of person authorized to sign on behalf of
assignee

A "STATEMENT UNDER 37 C.F.R. § 3.73(b)" is attached.

Assignment recorded in PTO on mailed with Application on 10/12/2000

Reel _____ Frame _____

Reg. No.: 37008

Tel. No.: (978) 927-5054 X:373

Customer No.: 28986

SIGNATURE OF PRACTITIONER

Harriet M. Strimpel, D.Phil.

(type or print name of practitioner)

Patent Counsel

New England Biolabs, Inc.

P.O. Address

32 Tozer Road

Beverly, MA 01915

(Submission—Nucleotide and/or Amino Acid Sequence [9-37]—page 6 of 6)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/689,343	10/12/2000	Romualdas Vaisvila	NEB-181	7976

28986 7590 09/24/2002

NEW ENGLAND BIOLABS, INC.
32 TOZER ROAD
BEVERLY, MA 01915

EXAMINER

GUZO, DAVID

ART UNIT	PAPER NUMBER
----------	--------------

1636

DATE MAILED: 09/24/2002

15

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

15

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

SEE ATTACHMENT -

Art Unit: 1636

Attachment

The communication filed 7/2/02 is not fully responsive to the Office communication mailed 6/19/02 for the reason(s) set forth below or on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report.


If a complete reply has not been submitted by the time the shortened statutory period set in the communication mailed 6/19/02 has expired, this application will become abandoned unless applicant corrects the deficiency and obtains an extension of time under 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo whose telephone number is (703) 308-1906. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242. Faxes may be sent directly to the examiner at (703) 746-5061.

Any inquiry of a general nature or relating to the status of this application or proceeding or relating to attachments to this Office Action should be directed to Patent Analyst Zeta Adams whose telephone number is (703) 305-3291.

David Guzo
September 23, 2002

DAVID GUZO
PRIMARY EXAMINER




Applicant's *App*

Application No. 09/689343

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: _____

RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

Applicant must provide:


☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)


For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400



Applicants Copy

BIOTECHNOLOGY
SYSTEMS
BRANCH



1600

1636

#14

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/689,343c
Source: 1600
Date Processed by STIC: 7/19/02

RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

TECH CENTER 1600/2900


OCT 16 2002

RECEIVED

RECEIVED

AUG 14 2002

TECH CENTER 1600/2900



1600

Does Not Comply
Corrected Diskette Needed

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/689,343C

DATE: 07/19/2002

TIME: 14:59:20

Error on p. 5

Input Set : A:\NEB-181.ST25.txt

Output Set: N:\CRF3\07192002\I689343C.raw

RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

3 <110> APPLICANT: Vaisvila, Romualdas
 4 Morgan, Richard D.
 5 Kucera, Rebecca B.
 6 Claus, Toby B.
 7 Raleigh, Elisabeth A.
 9 <120> TITLE OF INVENTION: Method For Cloning And Producing The MseI Restriction
 Endonuclease
 11 <130> FILE REFERENCE: NEB-181
 13 <140> CURRENT APPLICATION NUMBER: US 09/689,343C
 14 <141> CURRENT FILING DATE: 2000-10-12
 16 <160> NUMBER OF SEQ ID NOS: 9
 18 <170> SOFTWARE: PatentIn version 3.1
 20 <210> SEQ ID NO: 1
 21 <211> LENGTH: 903
 22 <212> TYPE: DNA
 23 <213> ORGANISM: Micrococcus sp.
 25 <220> FEATURE:
 26 <221> NAME/KEY: CDS
 27 <222> LOCATION: (1)..(900)
 28 <223> OTHER INFORMATION:
 30 <400> SEQUENCE: 1
 32 atg cct atc tcg acc gtc tgg acg ccg gac gga gac gac ctc atc gtg 48
 33 Met Pro Ile Ser Thr Val Trp Thr Pro Asp Gly Asp Asp Leu Ile Val
 34 1 5 10 15
 36 gag gcg gac aac ctc gat ttc att caa acg ctc ccc gac gcg agc ttc 96
 37 Glu Ala Asp Asn Leu Asp Phe Ile Gln Thr Leu Pro Asp Ala Ser Phe
 38 20 25 30
 40 cga atg atc tac atc gat ccg ccg ttc aac aca ggg cga acg cag ccg 144
 41 Arg Met Ile Tyr Ile Asp Pro Pro Phe Asn Thr Gly Arg Thr Gln Arg
 42 35 40 45
 44 ctt cag tcg ctc aag acg acc cgc tcg gtc aca ggg tcg cga gtc ggc 192
 45 Leu Gln Ser Leu Lys Thr Thr Arg Ser Val Thr Gly Ser Arg Val Gly
 46 50 55 60
 48 ttc aaa ggc cag acg tac gac acg gtc aag agc act ctg cac tcg tat 240
 49 Phe Lys Gly Gln Thr Tyr Asp Thr Val Lys Ser Thr Leu His Ser Tyr
 50 65 70 75 80
 52 gac gac gct ttc acc gac tat tgg tcg ttc ctc gaa ccg cgt ctc ctg 288
 53 Asp Asp Ala Phe Thr Asp Tyr Trp Ser Phe Leu Glu Pro Arg Leu Leu
 54 85 90 95
 56 gag gct tgg cgg ttg ctc acc cct gac ggc gcg ctc tat ctt cat ctg 336
 57 Glu Ala Trp Arg Leu Leu Thr Pro Asp Gly Ala Leu Tyr Leu His Leu
 58 100 105 110
 60 gat tac cgc gag gtt cac tac gcc aag gtc gtc ctc gac gcg atg ttc 384
 61 Asp Tyr Arg Glu Val His Tyr Ala Lys Val Val Leu Asp Ala Met Phe

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/689,343C

DATE: 07/19/2002

TIME: 14:59:20

Input Set : A:\NEB-181.ST25.txt

Output Set: N:\CRF3\07192002\I689343C.raw

```

62      115      120      125
64 gga cgc gaa agc ttc ctg aac gag ctg atc tgg gcg tac gac tac ggc      432
65 Gly Arg Glu Ser Phe Leu Asn Glu Leu Ile Trp Ala Tyr Asp Tyr Gly
66      130      135      140
68 gcg cgc tcg aag agc aag tgg ccc acc aag cac gac aac atc ctc gtg      480
69 Ala Arg Ser Lys Ser Lys Trp Pro Thr Lys His Asp Asn Ile Leu Val
70 145      150      155      160
72 tat gtg aag gac ccg aac aac tac gtc tgg aac ggt cag gat gta gat      528
73 Tyr Val Lys Asp Pro Asn Asn Tyr Val Trp Asn Gly Gln Asp Val Asp
74      165      170      175
76 cgc gag ccc tac atg gcg ccc ggg ctc gtt aca ccc gag aag gta gcg      576
77 Arg Glu Pro Tyr Met Ala Pro Gly Leu Val Thr Pro Glu Lys Val Ala
78      180      185      190
80 ctt ggc aag ctg ccc acc gac gtc tgg tgg cac aca atc gtt ccg cct      624
81 Leu Gly Lys Leu Pro Thr Asp Val Trp Trp His Thr Ile Val Pro Pro
82      195      200      205
84 gcg agc aaa gag cgc acc ggg tac gcg aca cag aag ccg gtc ggc atc      672
85 Ala Ser Lys Glu Arg Thr Gly Tyr Ala Thr Gln Lys Pro Val Gly Ile
86      210      215      220
88 atc cgt cgc atg att cag gcg agc agc aat gaa ggc gac tgg gtt ctg      720
89 Ile Arg Arg Met Ile Gln Ala Ser Ser Asn Glu Gly Asp Trp Val Leu
90 225      230      235      240
92 gat ttc ttc gct ggt agt ggg acg acc ggc gcc gcg gcc cgc cag ctc      768
93 Asp Phe Phe Ala Gly Ser Gly Thr Thr Gly Ala Ala Ala Arg Gln Leu
94      245      250      255
96 gga cgc cgt ttt gtg ctc gta gac gtc aac cca gaa gca atc gcg gta      816
97 Gly Arg Arg Phe Val Leu Val Asp Val Asn Pro Glu Ala Ile Ala Val
98      260      265      270
100 atg gca aaa cgg ttg gat gac ggg gca ttg gac acc agc gtg acg atc      864
101 Met Ala Lys Arg Leu Asp Asp Gly Ala Leu Asp Thr Ser Val Thr Ile
102      275      280      285
104 gtg cag act ccc cag agt gac cca cga acc gac gga tga      903
105 Val Gln Thr Pro Gln Ser Asp Pro Arg Thr Asp Gly
106      290      295      300
109 <210> SEQ ID NO: 2
110 <211> LENGTH: 300
111 <212> TYPE: PRT
112 <213> ORGANISM: Micrococcus sp.
114 <400> SEQUENCE: 2
116 Met Pro Ile Ser Thr Val Trp Thr Pro Asp Gly Asp Asp Leu Ile Val
117 1      5      10      15
119 Glu Ala Asp Asn Leu Asp Phe Ile Gln Thr Leu Pro Asp Ala Ser Phe
120      20      25      30
122 Arg Met Ile Tyr Ile Asp Pro Pro Phe Asn Thr Gly Arg Thr Gln Arg
123      35      40      45
125 Leu Gln Ser Leu Lys Thr Thr Arg Ser Val Thr Gly Ser Arg Val Gly
126      50      55      60
128 Phe Lys Gly Gln Thr Tyr Asp Thr Val Lys Ser Thr Leu His Ser Tyr
129 65      70      75      80

```

RAW SEQUENCE LISTING

DATE: 07/19/2002

PATENT APPLICATION: US/09/689,343C

TIME: 14:59:20

Input Set : A:\NEB-181.ST25.txt

Output Set: N:\CRF3\07192002\I689343C.raw

```

131 Asp Asp Ala Phe Thr Asp Tyr Trp Ser Phe Leu Glu Pro Arg Leu Leu
132           85                      90                      95
134 Glu Ala Trp Arg Leu Leu Thr Pro Asp Gly Ala Leu Tyr Leu His Leu
135           100                     105                     110
137 Asp Tyr Arg Glu Val His Tyr Ala Lys Val Val Leu Asp Ala Met Phe
138           115                     120                     125
140 Gly Arg Glu Ser Phe Leu Asn Glu Leu Ile Trp Ala Tyr Asp Tyr Gly
141           130                     135                     140
143 Ala Arg Ser Lys Ser Lys Trp Pro Thr Lys His Asp Asn Ile Leu Val
144 145           150                     155                     160
146 Tyr Val Lys Asp Pro Asn Asn Tyr Val Trp Asn Gly Gln Asp Val Asp
147           165                     170                     175
149 Arg Glu Pro Tyr Met Ala Pro Gly Leu Val Thr Pro Glu Lys Val Ala
150           180                     185                     190
152 Leu Gly Lys Leu Pro Thr Asp Val Trp Trp His Thr Ile Val Pro Pro
153           195                     200                     205
155 Ala Ser Lys Glu Arg Thr Gly Tyr Ala Thr Gln Lys Pro Val Gly Ile
156           210                     215                     220
158 Ile Arg Arg Met Ile Gln Ala Ser Ser Asn Glu Gly Asp Trp Val Leu
159 225           230                     235                     240
161 Asp Phe Phe Ala Gly Ser Gly Thr Thr Gly Ala Ala Ala Arg Gln Leu
162           245                     250                     255
164 Gly Arg Arg Phe Val Leu Val Asp Val Asn Pro Glu Ala Ile Ala Val
165           260                     265                     270
167 Met Ala Lys Arg Leu Asp Asp Gly Ala Leu Asp Thr Ser Val Thr Ile
168           275                     280                     285
170 Val Gln Thr Pro Gln Ser Asp Pro Arg Thr Asp Gly
171           290                     295                     300

```

173 <210> SEQ ID NO: 3

174 <211> LENGTH: 1236

175 <212> TYPE: DNA

176 <213> ORGANISM: Unknown

178 <220> FEATURE:

179 <223> OTHER INFORMATION: Environmental DNA

181 <220> FEATURE:

182 <221> NAME/KEY: CDS

183 <222> LOCATION: (1)..(1233)

184 <223> OTHER INFORMATION:

186 <220> FEATURE:

187 <221> NAME/KEY: misc_feature

188 <222> LOCATION: (198)..(198)

189 <223> OTHER INFORMATION: Xaa = any amino acid

191 <220> FEATURE:

192 <221> NAME/KEY: misc_feature

193 <222> LOCATION: (594)..(594)

194 <223> OTHER INFORMATION: N= G, A, C or T

196 <400> SEQUENCE: 3

198 atg cct aca ctg gat tgg ccc ggt aaa cag tta agc ttc cca cca gct

48

199 Met Pro Thr Leu Asp Trp Pro Gly Lys Gln Leu Ser Phe Pro Pro Ala

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/689,343C

DATE: 07/19/2002

TIME: 14:59:21

Input Set : A:\NEB-181.ST25.txt

Output Set: N:\CRF3\07192002\I689343C.raw

```

266 aca acc gct gtg gtg gca gcc cgt ctg gga cgg cgc ttc ctg gtc aac      864
267 Thr Thr Ala Val Val Ala Ala Arg Leu Gly Arg Arg Phe Leu Val Asn
268      275      280      285
270 gat gca agc tgg cgc gcc gtt cat gtg aca cgc aca cgc ttg cta cgc      912
271 Asp Ala Ser Trp Arg Ala Val His Val Thr Arg Thr Arg Leu Leu Arg
272      290      295      300
274 gag gga gta agt ttc act ttt gaa cgc cag gaa act ttt act cta cct      960
275 Glu Gly Val Ser Phe Thr Phe Glu Arg Gln Glu Thr Phe Thr Leu Pro
276 305      310      315      320
278 atc cag cca ctt cca cca gat tgg ttg atc atc gcc gag gag caa att      1008
279 Ile Gln Pro Leu Pro Pro Asp Trp Leu Ile Ile Ala Glu Glu Gln Ile
280      325      330      335
282 cgc ctc caa gca ccc ttt ctc gta gat ttt tgg gaa gtg gac gat caa      1056
283 Arg Leu Gln Ala Pro Phe Leu Val Asp Phe Trp Glu Val Asp Asp Gln
284      340      345      350
286 tgg gat ggc aaa atc ttc cgc agc cgt cat caa ggc tta cgc tcc cgc      1104
287 Trp Asp Gly Lys Ile Phe Arg Ser Arg His Gln Gly Leu Arg Ser Arg
288      355      360      365
290 ctt cag gag cag gcg ccg ctc tct cta cca ttg acc ggg aat gga ctg      1152
291 Leu Gln Glu Gln Ala Pro Leu Ser Leu Pro Leu Thr Gly Asn Gly Leu
292      370      375      380
294 ttg tgt gta cgg gta gtg agc cgt gaa ggg gaa tac tat gag ttc aca      1200
295 Leu Cys Val Arg Val Val Ser Arg Glu Gly Glu Tyr Tyr Glu Phe Thr
296 385      390      395      400
298 ggt cga gcc gat agc cct cac ccc gta tcg ttt tga      1236
299 Gly Arg Ala Asp Ser Pro His Pro Val Ser Phe
300      405      410

```

```

303 <210> SEQ ID NO: 4
304 <211> LENGTH: 411
305 <212> TYPE: PRT
306 <213> ORGANISM: Unknown
308 <220> FEATURE:
309 <223> OTHER INFORMATION: Environmental DNA
311 <220> FEATURE:
312 <221> NAME/KEY: misc_feature
313 <222> LOCATION: (198)..(198)
314 <223> OTHER INFORMATION: Xaa = any amino acid
316 <220> FEATURE:
317 <221> NAME/KEY: misc_feature
318 <222> LOCATION: (594)..(594)
319 <223> OTHER INFORMATION: N= G, A, C or T
321 <400> SEQUENCE: 4

```

```

323 Met Pro Thr Leu Asp Trp Pro Gly Lys Gln Leu Ser Phe Pro Pro Ala
324 1      5      10      15
326 Thr Ser Leu His Leu Glu Ser Val Val Thr Glu Gly Ala Glu Ser Pro
327      20      25      30
329 Pro Asn Arg Leu Ile Trp Ala Asp Asn Leu Pro Leu Met Val Asp Leu
330      35      40      45
332 Leu Ala Glu Tyr Glu Gly Lys Ile Asp Leu Ile Tyr Ala Asp Pro Pro

```

← This is a protein sequence - amino acid
 R is not found at position 594

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/689,343C

DATE: 07/19/2002
TIME: 14:59:22

Input Set : A:\NEB-181.ST25.txt
Output Set: N:\CRF3\07192002\I689343C.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:3; N Pos. 594
Seq#:3; Xaa Pos. 198
Seq#:4; Xaa Pos. 198

VERIFICATION SUMMARY

DATE: 07/19/2002

PATENT APPLICATION: US/09/689,343C

TIME: 14:59:22

Input Set : A:\NEB-181.ST25.txt

Output Set: N:\CRF3\07192002\I689343C.raw

L:246 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:576

L:247 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:624

L:359 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:192